Dysbiosis: Imbalance in the structural or functional configuration of the microbiota, leading to a disruption of host-organism homeostasis. This has been demonstrated in multiple disease states such as functional bowel disorders, inflammatory bowel disease, cirrhosis, allergies, diabetes, and obesity.
Gnotobiotic: Describes laboratory mice that are in sterile (germ-free) conditions or colonized with a specific microorganism or microorganisms. Use of gnotobiotic mice has led to discoveries of the role that the microbiota play in carcinogenesis, chemotherapy metabolism, etc.
Microbiome:
The communities of microorganisms from the three kingdoms of bacteria, yeast, and archae plus viruses that populate a location such as the large intestine. The human microbiome consists overwhelmingly of bacteria, most of which colonize the large intestine.
Microbiota:
The assemblage of microorganisms that exists in a previously established environment. This is the preferred term for the microbiome. The gut microbiota was also formerly called the gut flora. More than 1000 species can be found in the human gut microbiota but only 150 to 170 predominate in any one person.
Mutualistic: Mutually beneficial.
Prebiotic: Non-digestible food components that stimulate the activity or the growth of the beneficial intestinal bacteria termed bifidobacteria and lactobacillus. Examples include fermented foods (sauerkraut, kimchi, kefir); cultured foods (yogurt, revolutionary understandings of health, disease, and therapeutic interventions.
Truly, we have discovered an entirely new organ system that not only is responsible for proper intestinal functioning including gut motility, immunity, and permeability but also plays an important role in previously unrelated topics as osteoporosis, anxiety, pain perception, adiposity, and carcinogenesis. This means that all health professionals are now challenged to come up to speed on this newly emerging cross-disciplinary field of inquiry. To foster such professional growth and development, this issue of Global Advances in Health and Medicine has assembled a variety of perspectives on the power of the human microbiome. For example, noted visionary Patrick Hanaway, MD, opens the issue by addressing the topic of diversity. He reminds us that the composition of our microbiota is unique to each person and that like every ecological system, resilience depends upon preservation of diversity. Award-winning journalist Steve LeBeau interviews Alexander Khoruts, MD, one of the leaders in the new world of fecal microbial transplants. Dr Khoruts reviews the US Food and Drug Admin istration's current regulations and proposes ways to advance the field. Readers will also find several original articles, three provocatively exciting reviews from leaders in their field, and an original case study. For readers, this issue guarantees new insights into how understanding the microbiome will revolutionize care.
To support every reader's entrée into this new topic, the editors have included the following glossary. We know that in this issue, you will again find Global Advances in Health and Medicine living up to its name and promise. And, as always, we welcome your feedback and comments.
